Literature DB >> 28401935

Unique invariant natural killer T cells promote intestinal polyps by suppressing TH1 immunity and promoting regulatory T cells.

Y Wang1, S Sedimbi1, L Löfbom1, A K Singh1, S A Porcelli2, S L Cardell1.   

Abstract

CD1d-restricted invariant natural killer T (iNKT) cells are known as potent early regulatory cells of immune responses. Besides the established roles in the regulation of inflammation and autoimmune disease, studies have shown that iNKT cells have important roles in tumor surveillance and the control of tumor metastasis. Here we found that the absence of iNKT cells markedly decreased the total number of intestinal polyps in APCMin/+ mice, a model for colorectal cancer. Polyp iNKT cells were enriched for interleukin-10 (IL-10)- and IL-17-producing cells, showed a distinct phenotype being CD4+, NK1.1- CD44int, and PD-1lo, and they were negative for the NKT cell transcription factor promyelocytic leukemia zinc-finger. The absence of iNKT cells was associated with a reduced frequency of regulatory T (Tregs) cells and lower expression levels of FoxP3 protein and transcript uniquely in the polyps, and a switch to an inflammatory macrophage phenotype. Moreover, in iNKT cell-deficient APCMin/+ mice, expression of T-helper (TH) 1-associated genes, such as IFN-γ and Nos2, was increased in polyps, concomitantly with elevated frequencies of conventional CD4+ and CD8+ T cells in this tissue. The results suggest that a population of regulatory iNKT cells locally promote intestinal polyp formation by enhancing Treg cells and immunosuppression of antitumor TH1 immunity.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28401935      PMCID: PMC5638666          DOI: 10.1038/mi.2017.34

Source DB:  PubMed          Journal:  Mucosal Immunol        ISSN: 1933-0219            Impact factor:   7.313


  47 in total

Review 1.  NKT cells - conductors of tumor immunity?

Authors:  Mark J Smyth; Nadine Y Crowe; Yoshihiro Hayakawa; Kazuyoshi Takeda; Hideo Yagita; Dale I Godfrey
Journal:  Curr Opin Immunol       Date:  2002-04       Impact factor: 7.486

2.  Inhibition of antitumor immunity by invariant natural killer T cells in a T-cell lymphoma model in vivo.

Authors:  Gourapura J Renukaradhya; Venkataraman Sriram; Wenjun Du; Jacquelyn Gervay-Hague; Luc Van Kaer; Randy R Brutkiewicz
Journal:  Int J Cancer       Date:  2006-06-15       Impact factor: 7.396

3.  Ablation of IL-17A abrogates progression of spontaneous intestinal tumorigenesis.

Authors:  Wook-Jin Chae; Thomas F Gibson; Daniel Zelterman; Liming Hao; Octavian Henegariu; Alfred L M Bothwell
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-08       Impact factor: 11.205

Review 4.  The immunoregulatory role of type I and type II NKT cells in cancer and other diseases.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Cancer Immunol Immunother       Date:  2014-01-03       Impact factor: 6.968

5.  CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.

Authors:  Y Naito; K Saito; K Shiiba; A Ohuchi; K Saigenji; H Nagura; H Ohtani
Journal:  Cancer Res       Date:  1998-08-15       Impact factor: 12.701

6.  The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells.

Authors:  H Kitamura; K Iwakabe; T Yahata; S Nishimura; A Ohta; Y Ohmi; M Sato; K Takeda; K Okumura; L Van Kaer; T Kawano; M Taniguchi; T Nishimura
Journal:  J Exp Med       Date:  1999-04-05       Impact factor: 14.307

7.  The alarmin IL-33 promotes regulatory T-cell function in the intestine.

Authors:  Chris Schiering; Thomas Krausgruber; Agnieszka Chomka; Anja Fröhlich; Krista Adelmann; Elizabeth A Wohlfert; Johanna Pott; Thibault Griseri; Julia Bollrath; Ahmed N Hegazy; Oliver J Harrison; Benjamin M J Owens; Max Löhning; Yasmine Belkaid; Padraic G Fallon; Fiona Powrie
Journal:  Nature       Date:  2014-07-16       Impact factor: 49.962

8.  iNKT cells suppress the CD8+ T cell response to a murine Burkitt's-like B cell lymphoma.

Authors:  Ryan L Bjordahl; Laurent Gapin; Philippa Marrack; Yosef Refaeli
Journal:  PLoS One       Date:  2012-08-07       Impact factor: 3.240

9.  Transforming growth factor-beta production and myeloid cells are an effector mechanism through which CD1d-restricted T cells block cytotoxic T lymphocyte-mediated tumor immunosurveillance: abrogation prevents tumor recurrence.

Authors:  Masaki Terabe; So Matsui; Jong-Myun Park; Mizuko Mamura; Nancy Noben-Trauth; Debra D Donaldson; Wanjun Chen; Sharon M Wahl; Steven Ledbetter; Bruce Pratt; John J Letterio; William E Paul; Jay A Berzofsky
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

Review 10.  NKT cells as an ideal anti-tumor immunotherapeutic.

Authors:  Shin-Ichiro Fujii; Kanako Shimizu; Yoshitaka Okamoto; Naoki Kunii; Toshinori Nakayama; Shinichiro Motohashi; Masaru Taniguchi
Journal:  Front Immunol       Date:  2013-12-02       Impact factor: 7.561

View more
  26 in total

1.  Impacts of the MHC class I-like XNC10 and innate-like T cells on tumor tolerance and rejection in the amphibian Xenopus.

Authors:  Maureen Banach; Eva-Stina Edholm; Xavier Gonzalez; Abdellatif Benraiss; Jacques Robert
Journal:  Carcinogenesis       Date:  2019-07-20       Impact factor: 4.944

2.  Control of Tissue-Resident Invariant NKT Cells by Vitamin A Metabolites and P2X7-Mediated Cell Death.

Authors:  Qingyang Liu; Chang H Kim
Journal:  J Immunol       Date:  2019-07-15       Impact factor: 5.422

Review 3.  Adoptive Immunotherapy With Engineered iNKT Cells to Target Cancer Cells and the Suppressive Microenvironment.

Authors:  Gloria Delfanti; Paolo Dellabona; Giulia Casorati; Maya Fedeli
Journal:  Front Med (Lausanne)       Date:  2022-05-09

4.  Regulatory T cells specifically suppress conventional CD8αβ T cells in intestinal tumors of APCMin/+ mice.

Authors:  Louis Szeponik; Paulina Akeus; William Rodin; Sukanya Raghavan; Marianne Quiding-Järbrink
Journal:  Cancer Immunol Immunother       Date:  2020-03-17       Impact factor: 6.968

5.  Dietary and Microbial Oxazoles Induce Intestinal Inflammation by Modulating Aryl Hydrocarbon Receptor Responses.

Authors:  Shankar S Iyer; Thomas Gensollen; Amit Gandhi; Sungwhan F Oh; Joana F Neves; Frederic Collin; Richard Lavin; Carme Serra; Jonathan Glickman; Punyanganie S A de Silva; R Balfour Sartor; Gurdyal Besra; Russell Hauser; Anthony Maxwell; Amadeu Llebaria; Richard S Blumberg
Journal:  Cell       Date:  2018-05-17       Impact factor: 41.582

6.  Distinct iNKT Cell Populations Use IFNγ or ER Stress-Induced IL-10 to Control Adipose Tissue Homeostasis.

Authors:  Nelson M LaMarche; Harry Kane; Ayano C Kohlgruber; Han Dong; Lydia Lynch; Michael B Brenner
Journal:  Cell Metab       Date:  2020-06-08       Impact factor: 27.287

Review 7.  Tissue-specific functions of invariant natural killer T cells.

Authors:  Catherine M Crosby; Mitchell Kronenberg
Journal:  Nat Rev Immunol       Date:  2018-09       Impact factor: 53.106

8.  Calcium signals regulate the functional differentiation of thymic iNKT cells.

Authors:  Meng Zhao; Ariel Quintana; Chen Zhang; Alexander Y Andreyev; William Kiosses; Tomomi Kuwana; Anne Murphy; Patrick G Hogan; Mitchell Kronenberg
Journal:  EMBO J       Date:  2021-06-25       Impact factor: 14.012

9.  Paracrine cyclooxygenase-2 activity by macrophages drives colorectal adenoma progression in the Apc Min/+ mouse model of intestinal tumorigenesis.

Authors:  Mark A Hull; Richard J Cuthbert; C W Stanley Ko; Daniel J Scott; Elizabeth J Cartwright; Gillian Hawcroft; Sarah L Perry; Nicola Ingram; Ian M Carr; Alexander F Markham; Constanze Bonifer; P Louise Coletta
Journal:  Sci Rep       Date:  2017-07-20       Impact factor: 4.379

10.  MAP3K2 augments Th1 cell differentiation via IL-18 to promote T cell-mediated colitis.

Authors:  Ningbo Wu; Dongping Chen; Hongxiang Sun; Jianmei Tan; Yao Zhang; Tianyu Zhang; Yuheng Han; Hongzhi Liu; Xinxing Ouyang; Xiao-Dong Yang; Xiaoyin Niu; Jie Zhong; Zhengting Wang; Bing Su
Journal:  Sci China Life Sci       Date:  2020-07-28       Impact factor: 6.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.